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K-Ras and Dpc4 Mutations in Chronic Pancreatitis: Case Series
Aim To assess whether alterations in the K-ras, p53, and DPC4 genes 
are present in pancreatitis, a potential precancerous condition that 
can progress to pancreatic adenocarcinoma. To investigate the altera-
tions occurring at hot spots of K-ras (exon 1), p53 (exons 5 and 7), 
and DPC4 (exons 8, 10 and 11).
Methods In 10 patients with acute and 22 with chronic pancreatitis, 
without pancreatic intraepithelial neoplasia (PanIN), DNA was iso-
lated from paraffin embedded tissue samples. The extracted DNA was 
analyzed by polymerase chain reaction (PCR), restriction fragment 
length polymorphism (RFLP) analysis, single-strand conformation 
polymorphism (SSCP) analysis, and DNA sequencing.
Results In acute pancreatitis samples no mutations were found in any 
of the investigated genes. In 7 out of 22 samples of chronic pancre-
atitis nucleotide substitution at exon 1 of K-ras (five at codon 12 and 
two at codon 13) were found. No mutations in p53 (exons 5 and 7) 
were detected. Two samples had nucleotide substitutions at exons 8 
and 11 of DPC4, introducing STOP signal and change in the amino 
acid sequence, respectively. One chronic pancreatitis sample displayed 
simultaneous mutations in K-ras (exon 1, codon 12) and DPC4 (exon 
8, codon 358).
Conclusion Mutations of K-ras and Dpc4 genes can accumulate al-
ready in non-malignant, inflammatory pancreatic tissue, suggesting its 
applicability in monitoring of further destruction of pancreatic tissue 
and progression into malignancy.
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Pancreatitis is an inflammatory disease of the 
pancreas, characterized by the progressive tissue 
destruction, leading both to exocrine and endo-
crine insufficiency. Acute pancreatitis can mani-
fest as a benign condition with minimal abdom-
inal pain and hyperamylasemia, or can have a 
fulminate course due to the development of in-
fective pancreatic necrosis and multisystem or-
gan failure (1).
On the other hand, chronic pancreatitis is 
characterized by the progressive destruction of 
pancreatic parenchyma and its replacement by 
variable amounts of fibrous tissue (2). A charac-
teristic histological profile displays a fibrosis in 
association with the foci of inflammatory cells, 
the regions of acinar cell degradation, and the ar-
eas of ductal cell proliferation (3).
Diagnosing pancreatitis at an early stage is a 
clinical challenge, because the frequency of pan-
creatic ductal adenocarcinoma in patients with 
pre-existing chronic pancreatitis is significant-
ly higher than in the general population. It has 
been shown that chronic pancreatitis increases 
the risk of developing pancreatic cancer 10 to 20 
times (4). Progression model of pancreatic duc-
tal adenocarcinoma at the molecular level shows 
that it always harbors K-ras, p53, and p16 altera-
tions, and also mutations in the DPC4 (deleted 
in pancreatic cancer gene, locus 4) (5-7). In con-
trast to pancreatic cancer, the molecular mecha-
nism responsible for acute and chronic pancreati-
tis is poorly understood. Some improvement has 
been made with the discovery of the genetic na-
ture of hereditary pancreatitis (8,9). The stud-
ies of molecular alterations occurring in acute 
and chronic pancreatitis have mainly included 
the investigation of alterations in cationic tryp-
sinogen gene, K-ras, p53, or cystic fibrosis trans-
membrane conductance regulator gene (CFTR) 
(8,10-14).
Since pancreatitis represents a precancer-
ous state in a considerable number of cases, we 
assumed that the alterations in more than one 
gene could be associated with the genetic basis 
of the disease and the genes involved in the de-
velopment of pancreatic adenocarcinoma could 
be mutated already in pancreatitis. Therefore, 
in collected tissue samples of acute and chronic 
pancreatitis, we investigated the alterations oc-
curring at hot spots of three different genes (K-
ras, p53, DPC4) which are members of different 
signaling pathways.
Material and methods
Patients and genomic DNA preparation
Postmortem pancreatitis samples were ob-
tained from 10 patients with acute pancreati-
tis and 22 patients with chronic pancreatitis be-
tween 1998 and 2003. For the purposes of this 
study, the samples were retrieved from the archi-
val tissue files of the Zagreb University Hospital 
Center, Department of Pathology. Histologi-
cal sections cut from 10% buffered formalin-
fixed paraffin-embedded blocks were routinely 
stained with hematoxylin and eosin. Diagnosis 
of acute and chronic pancreatitis without pan-
creatic intraepithelial neoplasia (PanIN) was 
confirmed by the same pathologist (J. J. R.) for 
all samples.
Paraffin-embedded sections (4 µm) were 
fixed to the slides, and 2-3 sections were used for 
one-step DNA extraction by TaKaRa DEXPAT 
TM (TaKaRa Bio Europe, Inc, Gennevilliers, 
France) according to manufacturer’s instruc-
tions. Three separate DNA extracts were pre-
pared from each paraffin embedded block.
Polymerase chain reactions
Genomic DNA from the sections was amplified 
by polymerase chain reactions (PCR) in a final 
reaction volume of 25 µL containing lx HotMas-
ter Taq Buffer (Eppendorf, Hamburg, Germa-
ny), 50 µmol/L of each dNTP (Eppendorf), 5 
pmol of forward and reverse primers, 1 U Hot-
Master Taq DNA polymerase (Eppendorf), and 
2.5 µL of extracted DNA (50-100 ng).
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PCR was performed under conditions of an 
initial denaturation at 94°C for 2 minutes, 30-
40 cycles consisted of denaturation (30 seconds 
at 94°C), annealing (30 seconds at 51-58°C, de-
pending on the primer) and elongation step (30 
seconds at 72°C), and a final extension step at 
72°C for 7 minutes. Reactions were performed 
in a BioSystems Thermocycler 2700 (Applied 
BioSystems, Foster City, CA, USA). Each PCR 
batch was tested three times and always includ-
ed a blank to which no DNA had been added, to 
ensure that no contamination of samples had oc-
curred. Sequences of primers designed for PCR 
reaction are listed in Table 1. The PCR products 
were visualized in ethidium bromide-stained 3% 
agarose gel.
All pancreatitis samples were screened for 
mutation within coding region by two analyses: 
PCR-restriction fragment length polymorphism 
analysis (RFLP) for detection of previously doc-
umented mutation based on restriction site, and 
PCR-single strand conformation polymorphism 
analysis (SSCP) for searching for other muta-
tions in the analyzed samples.
PCR-RFLP
PCR-RFLP analysis was used in order to detect 
mutations in the hot spots of K-ras (codons 12 
and 13), p53 (codons 175 and 248), and DPC4 
(codons 358, 412, and 493) genes.
Two PCR amplification rounds were per-
formed for mutational analysis at exon 1 of the 
K-ras gene (15). PCR products were digested 
with Bst NI (New England BioLabs, Inc., Frank-
furt, Germany) for testing mutation at codon 12, 
and with Bgl I (BioLabs) for revealing mutation 
at codon 13, under the reaction conditions rec-
ommended by the supplier.
p53 mutations were identified using PCR 
amplification, followed by restriction with Cfo 
(BioLabs) enzyme (exon 5, codon 175), and 
with MspI (BioLabs) enzyme (exon 7, codon 
248).
The screen for mutation in the DPC4 gene 
involved exons 8 (codon 358), 10 (codon 412), 
and 11 (codon 493), under the same conditions 
as published in our previous study (16).
RFLP products of analyzed genes were sep-
arated on Spreadex EL 300 or EL 400 gels (El-
chrom Scientific, Cham, Switzerland). A 6 µL of 
restriction mixture, together with 1 µL of loading 
buffer (Eppendorf) were loaded onto gel, which 
was subsequently stained with Sybr Gold (Mo-
lecular Probes, Leiden, Netherlands) for 30 min-
utes, destained in distilled water, and analyzed on 
UV transilluminator at 254 nm.
PCR-SSCP
All specimens of pancreatitis tissue were screened 
for other mutations within the coding region of 
K-ras (exon 1), p53 (exons 5 and 7), and DPC4 
(exons 8, 10 and 11) by PCR-SSCP analysis.
A 5 µL of PCR product was mixed with 7 µL 
of formamide with 10 mmol/L NaOH. The mix-
ture was heated at 95°C for 5 minutes and then 
immediately placed on ice. Samples were separat-
ed by electrophoresis in 8% polyacrylamide gels 
at +4°C. The gels were silver stained.











K-ras  12 ACTGAATATAAACTTGTGGTAGTTGGACCT, TCAAAGAATGGTCCTGGACC, 
TAATATGTCGACTAAAACAAGATTTACCTC
5 GGT>GAT, TGT, 
GTT, GCT or GAT




p53 175 TGTTCACTTGTGCCCTGACT, CAGCCCTGTCGTCTCTCC 0 -
p53 248 CCTCATCTTGGGCCTGT, CCAGGGGTCAGCGGCAAGCA 0 -
DPC4 358 CTCCTGAGTATTGGTGTTCC, CTTGCTCTCTCAATGGCTTC 1* c.1203G>T
DPC4 412 TTGCGTCAGTGTCATCGACAA, GATAGCTGGAGCTATTCCAC 0 -
DPC4 539 TCTGTCAGCTGCTGCTGGAA, GGTTGTGGGTCTGCAATCGG 1 c.1744T>G
*Sample also positive to K-ras/12 mutation.
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Sequence analysis of PCR products
PCR product of the sample which revealed ab-
errant PCR-SSCP pattern was directly re-am-
plified from the Spreadex EL 1200 gel and then 
purified using a QIAquick column (QIAGEN 
Companies, Valencia, CA, USA) according to 
the manufacturer’s instructions. One microgram 
of purified PCR product in volume of 50 µL was 
sequenced by ABI PRISM Big Dye Terminator 
Cycle Sequencing Ready Reaction FS Kit and an 




PCR-RFLP analysis of exon 1 of the K-ras 
showed nucleotide substitution at codon 12 in 5 
samples (Figure 1A) and at codon 13 in 2 sam-
ples of chronic pancreatitis (Figure 1B). One 
sample with mutation at codon 12 of K-ras was 
also positive to DPC4 mutation (Table 1). None 
of the samples had patterns showing aberrant 
SSCP variants.
p53
PCR-RFLP analysis of the p53 gene revealed no 
mutations at exon 5 (codon 175) and exon 7 (co-
don 248) in all 32 pancreatitis samples (Table 
1). Moreover, no aberrant profile in PCR-SSCP 
analysis of these samples was detected.
DPC4
A single chronic pancreatitis sample showed the 
nucleotide substitution GGA→TGA, introduc-
ing STOP signal instead of Gly at exon 8 (Figure 
2). The same sample also had a mutation at co-
don 12 of the K-ras gene (Table 1). Additional 
PCR-SSCP analysis of DPC4 indicated the pres-
ence of a mutation in another sample of chronic 
pancreatitis (Figure 3A). Sequence analysis con-
firmed that indication, revealing GTA→GGA 
substitution at exon 11 (codon 539) which 
causes a change in the amino acid sequence 
(Val→Gly) (Figure 3B).
Discussion
This study presents the evidence of alterations 
in K-ras and DPC4 genes, but not in p53 gene, 
in paraffin embedded tissue samples of chronic 
pancreatitis. Inflammation within the pancreatic 
ducts could cause alterations in numerous genes 
that belong to different pathways (17). We spec-
ulate that the mutations we observed could be 
involved in malignant transformation and there-
fore mark pre-malignant pancreatic state.
The analysis performed on acute pancreati-
tis samples showed the absence of mutations at 
any analyzed locus of all tested genes. This find-
ing is consistent with the fact that most cases of 
acute pancreatitis recover without long-term se-
Figure 1. K-ras gene profile (exon 1) of chronic pancreatitis samples 
after RFLP analysis. (A) 157 bp fragment represents mutation (+) at 
codon 12 and 128 bp fragment represents wild type allele (-). (B) 157 
bp fragment represents mutation (+) at codon 13 and 125 bp fragment 
represents wild type (-) allele. M – molecular weight DNA marker IX 
(Boehringer, Mannheim, Germany).
Figure 2. DPC4 gene profile (exon 8) of chronic pancreatitis samples 
after RFLP analysis. Mutant allele (+) lacks Mnl l restriction site at 
codon 358, resulting with 184 bp fragment and wild type allele (-) is 
cut by Mnl l at codon 358 resulting with 117 bp and 67 bp fragments. 
M – molecular weight DNA marker M3 (Elchrom Scientific); uc – uncut 
PCR product.
Croat Med J 2007;48:218-224
222
quel, with only a minority of cases progressing to 
chronic pancreatitis (1,18,19). The time to accu-
mulate mutations due to inflammation is thus 
shortened, and cells are destroyed rather than al-
tered.
Of all genes tested in this study, K-ras exhibit-
ed the highest frequency of mutations in chronic 
pancreatitis samples; 5 samples (23%) were posi-
tive in the codon 12 and 2 (9%) in the codon 13. 
These results were not unexpected because the 
presence of K-ras mutation is not rare in patients 
with chronic pancreatitis, as validated by sever-
al groups, which found K-ras mutations in 39% 
(20), 28% (21), or 34% (22) of patients with 
chronic pancreatitis. These data indicate that K-
ras alterations could be taken as a risk factor for 
pancreatic ductal adenocarcinoma, although the 
sequence of events and the time required for con-
version to an established malignancy is very hard 
to define. In contrast to our results, two groups 
came to the conclusion that this mutation is ex-
ceedingly uncommon within the paraffin-em-
bedded pancreatitis specimens. They demon-
strated the total absence of K-ras (codons 12 and 
13) mutations in samples of chronic pancreatitis 
(2,12).
Furthermore, we also analyzed the p53 gene 
at mutational hot spots, exon 5 and 7. No p53 
gene mutations were discovered in the analyzed 
pancreatitis samples, which is consistent with 
prior observations that these mutations occur 
in chronic pancreatitis tissues only occasional-
ly (11,23), in contrast to pancreatic carcinomas, 
where the occurrence is almost 50% (23-25). On 
the other hand, our results are in opposition to 
those obtained by one research group (12) pre-
senting the evidence for early occurrence of p53 
(exons 5-9) mutations in chronic pancreatitis. 
Eight of 80 samples displayed alterations in p53 
detected by PCR-SSCP analysis and confirmed 
by DNA sequence analysis. The authors suggest-
ed that mutations in p53 could also occur at an 
early stage of pancreatic disease, without mor-
phological evidence of pancreatic cancer, as has 
been found in benign or precancerous lesions in 
other human tissues, such as hyperplastic pros-
tatic epithelium (26) and fibroadenoma of the 
breast (27). The accumulated data suggest that 
we should continue to investigate some addition-
al exons of p53 in a larger series of patients with 
chronic pancreatitis.
In this study, we also focused on the DPC4 
gene, whose protein mediates signals from the 
family of ligands of transforming growth factor-β 
signaling pathway (28). In 2 of 22 examined sam-
ples, mutations in C-terminal region of DPC4 
were found. One sample revealed nucleotide sub-
stitution at codon 358 (exon 8) which is incor-
porated into the mutation cluster region of the 
gene (29), and another sample had a single nucle-
otide substitution at codon 539 (exon 11). This 
is an interesting finding because previous molec-
ular studies showed that inactivating mutation 
of the DPC4 gene is a late genetic change in the 
multistep progression model of pancreatic ductal 
Figure 3. DPC4 gene mutation (exon 11) in one chronic pancreatitis 
sample. (A), PCR-SSCP analysis of the DNA fragment (asterisk indi-
cates abberant SSCP pattern). (B), Sequence analysis of the same 
DNA fragment points out single nucleotide substitution at codon 539.
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adenocarcinomas contributing to tumor progres-
sion (30-33). Mutations occurring at the exons 
of DPC4 gene have never been found in pancre-
atitis tissues. One chronic pancreatitis sample 
in our study displayed simultaneous mutations 
in K-ras (codon 12) and DPC4 (exon 8) genes. 
To our knowledge, only one group detected co-
inciding alterations of K-ras and DPC4 genes in 
non-tumoral pancreatic disease (34). But in that 
study, pancreatic juice of patients with chronic 
pancreatitis was sampled and only codon 12 of 
K-ras was analyzed.
Our study demonstrated that DPC4 muta-
tions might be present already in non-malignant 
tissue such as that of chronic pancreatitis, which 
is considered to have a potential for malignant 
transformation. The significance of these muta-
tions and their consequences should be clarified 
in the future. Nevertheless, the finding of mutat-
ed DPC4 in chronic pancreatitis suggests an in-
volvement of mutation in the progression of the 
disease toward malignancy.
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